10.72

3.77% -0.42

After Hours: 10.72

Design Therapeutics Inc (DSGN)

Overview News Price History Option Chain Financials Discussions Forecast

Design Therapeutics Inc stock is traded at $10.72, with a volume of 626.11K. It is down -3.77% in the last 24 hours and down -25.40% over the past month. Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Previous Close:

$11.14

Open:

$11.14

24h Volume:

626.11K

Relative Volume:

0.87

Market Cap:

$669.54M

Revenue:

Net Income/Loss:

$-69.71M

P/E Ratio:

-8.982

EPS:

-1.1935

Net Cash Flow:

$-54.12M

1W Performance:

+1.61%

1M Performance:

-25.40%

6M Performance:

+11.43%

1Y Performance:

+177.00%

1-Day Range:

$10.45

$11.24

1-Week Range:

$10.31

$11.36

52-Week Range:

$3.33

$17.25

Design Therapeutics Inc Stock (DSGN) Company Profile

Name

Design Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

858-293-4900

Address

6005 HIDDEN VALLEY ROAD, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

DSGN's Discussions on Twitter

Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DSGN Design Therapeutics Inc	10.72	695.77M	0	-69.71M	-54.12M	-1.1935
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	Jefferies	Buy
Jan-07-26	Initiated	Oppenheimer	Outperform
Dec-03-25	Initiated	Craig Hallum	Buy
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-20-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral
May-04-23	Upgrade	Goldman	Sell → Neutral
Jun-10-22	Initiated	Wedbush	Outperform
May-02-22	Initiated	RBC Capital Mkts	Outperform
Jan-19-22	Initiated	Goldman	Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-20-21	Initiated	Piper Sandler	Overweight
Apr-20-21	Initiated	SVB Leerink	Outperform

View All

Design Therapeutics Inc Stock (DSGN) Latest News

Jun 15, 2026

Design Therapeutics (DSGN) Gains 2.28% – Approaching Key Resistance at $11.78Weekly Profile - newsline.com

Jun 15, 2026

Jun 14, 2026

DSGN Q1 2026 Earnings: EPS Beat as Net Loss NarrowsEarnings Expansion Phase - newsline.com

Jun 14, 2026

Jun 11, 2026

Design Therapeutics Stockholders Approve Director and Auditor at Meeting - TipRanks

Jun 11, 2026

Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 - Stock Titan

Jun 11, 2026

[Form 4] Design Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 11, 2026

Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike - Stock Titan

Jun 11, 2026

Director at Design Therapeutics (DSGN) awarded options on 30,000 shares - Stock Titan

Jun 11, 2026

Design Therapeutics (DSGN) grants director David Shapiro 30,000 options - Stock Titan

Jun 11, 2026

Director at Design Therapeutics (DSGN) awarded 30,000 stock options - Stock Titan

Jun 11, 2026

Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes - Stock Titan

Jun 11, 2026

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire

Jun 11, 2026

Jun 09, 2026

DSGN Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineSubscription Growth Report - newsline.com

Jun 09, 2026

Point72-affiliated holders report 5.1% stake in Design Therapeutics (DSGN) - Stock Titan

Jun 09, 2026

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance

Jun 09, 2026

Jun 08, 2026